Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
Geoffrey Y. Ku(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Cornell University), James P. Allison(The University of Texas MD Anderson Cancer Center), Sebastian Edoardo Artur Schroeder(Memorial Sloan Kettering Cancer Center), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Richard D. Carvajal(Northwell Health), Jianda Yuan, Katherine S. Panageas(Mayo Clinic), David B. Page(Memorial Sloan Kettering Cancer Center), Gary K. Schwartz(Baylor University Medical Center)
Cited by 422
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k